Abstract | PURPOSE: EXPERIMENTAL DESIGN: In a phase 1 trial evaluating the safety and efficacy of carfilzomib in relapsed or refractory hematologic malignancies, eight dose groups of three to six patients received 5 consecutive days of carfilzomib i.v. push at doses of 1.2, 2.4, 4, 6, 8.4, 11, 15, and 20 mg/m2 within 14-day cycles. RESULTS: CONCLUSION:
|
Authors | Owen A O'Connor, A Keith Stewart, Marcy Vallone, Christopher J Molineaux, Lori A Kunkel, John F Gerecitano, Robert Z Orlowski |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 22
Pg. 7085-91
(Nov 15 2009)
ISSN: 1557-3265 [Electronic] United States |
PMID | 19903785
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Oligopeptides
- Protease Inhibitors
- Proteasome Inhibitors
- carfilzomib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Hematologic Neoplasms
(drug therapy)
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Oligopeptides
(therapeutic use)
- Protease Inhibitors
(therapeutic use)
- Proteasome Inhibitors
- Treatment Outcome
|